Skip to main content
Have a personal or library account? Click to login
Genotypes of Esbl Producing Escherichia Coli and Klebsiella Pneumoniae in Relation to Resistance to Antimicrobial Drugs Cover

Genotypes of Esbl Producing Escherichia Coli and Klebsiella Pneumoniae in Relation to Resistance to Antimicrobial Drugs

Open Access
|Dec 2014

References

  1. 1. Bradford PA. Extended-spectrum β-lactamases in the 21century: characterization, epidemiology and detection of this important resistance threat. Clin Micro-biol Rev. 2001; 14: 933–951.
  2. 2. Dashti AA, Jadaon MM, Habeeb FM. Can we rely on one laboratory test in detection of extended-spectrum β-lactamases among? An evaluation of the Vitek 2 system and comparison with four other detection methods in Kuwait. J Clin Pathol. 2009; 62: 739–742.
  3. 3. Lal K, Kapil A, Das BK, Sood S. Occurrence of TEM & SHV gene in extended spectrum β-lactamases (ESBLs) producingsp. Isolated from tertiary care hospital. Indian J Med Res. 2007; 125: 173–178.
  4. 4. Luzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Ste-fani S, Amicosante G, Rossolini GM, Toniolo A. Trends in production of extended-spectrum βl-lacta-mases amongof medical interest: report of the second Italian nationwide survey. J Clin Microbiol. 2006; 44: 1659–1664.
  5. 5. www. lahey clinic.org, last modified, august 2013.
  6. 6. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum β-lac-tamases in members of the familyin Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002; 46: 196–202.
  7. 7. Harada S, Ishii Y, Yamaguchi K. Extended-spectrum β-lactamases: Implications for the clinical laboratory and therapy. Korean J Lab Med. 2008; 28: 401–12.
  8. 8. Oliveira CF, Salla A, Lara VM, Rieger A, Horta JA, Alves SH. Prevalence of extended-spectrum beta-lac-tamases-producing microorganisms in nosocomial patients and molecular characterization of the SHV type isolates. Brasilian J Microb. 2010; 41: 278–282.
  9. 9. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM. Prevalence and spread of extended-spectrum β–lactamase-producingin Europe. Clin Microbiol Infect. 2008; 14: 144–153.
  10. 10. Kaftandzieva A, Kotevska V, Jankoska G, Kjurcik-Trajkovska B, Cekovska Z, Petrovska M. Extended-spectrum beta-lactamase-producingandin children at University Pediatric Clinic in Skopje.2009; 2: 36–41.
  11. 11. Kaftandzieva A, Kotevska V, Cekovska Z, Jankoska G, Kjurcik-Trajkovska B, Petrovska M. Prevalence and spread of extended-spectrum beta-lactamase-producingandat Univer sity Clinics in Skopje. Acta Morphol. 2009; 6: 66–71.
  12. 12. Kaftandzieva A, Trajkovska-Dokic E, Panovski N. Prevalence and molecular characterization of exten ded spectrum beta-lactamases (ESBL)-producingand. Contribu tions, Sec Biol Med Sci, MASA, XXXII/2, 2011: 129–141.
  13. 13. Kim J, Jeon S, Lee B, Park M, Lee H, Lee J, Kim S. Rapid detection of extended spectrum β-lactamase (ESBL) forby use of a multiplex PCR-based method. Infection and Chemotherapy. 2009; 41: 181–184.
  14. 14. Colom K, Perez J, Alonso R, Fernandez-Aranguiz A, Larino E, Cisterna RSimple and reliable multiplex PCR assay for detection of bla, blaand blagenes in.Microbiology Letters. 2003; 223: 147–151.
  15. 15. Jemima SA, Vergese S. Multiplex PCR for bla& blain the extended spectrum beta lactamase (ESBL) producing Gram-negative isolates. Indian J Med Res. 2008; 128: 313–317.
  16. 16. Shahcheraghi F, Nasiri S, Noveiri H. The survey of genes encoding beta-lactamases inresistant to beta-lactam and non-beta-lactam antibio tics. Iran J Basic Med Sci. 2010; 13: 230–237.
  17. 17. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, Sundsfjord A. Norwegian ESBL Study Group. Effects of phenotype and geno type on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates ofandin Norway. J Clin Microbiol. 2007; 45: 199–205.
  18. 18. Sorlozano A, Gutierrez J, Luna JD, Soto MJ, Piedrola G. In vitro activity of β-lactam and non-β-lactam antibiotics in extended-spectrum β-lactamase-producing clinical isolates ofDiagn Microbiol Infect Dis. 2006; 54: 135–139.
  19. 19. Navarro F, Miro E, Mirelis B. Interpretive reading of the antibiogram of enterobacteria. Enferm Infect Microbiol Clin. 2002; 20: 225–234.
  20. 20 Jain A, Mondal R. TEM & SHV genes in extended spectrum β-lactamase producingspecies & their antimicrobial resistance pattern. Indian J Med Res. 2008; 128: 759–764.
  21. 21. Perez F, Endimiani A, Hujer K, Bonomo R. The con tinuing challenge of ESBLs. Curr Opin Pharmacol. 2007; 7: 459–469.
  22. 22. Hadziyannis E, Tuohy M, Thomas L, Procop GW, Washington JA, Hall GS. Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in,andclinical isolates. Diagn Microbiol Infect Dis. 2000; 36: 113–117.
  23. 23. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17: 1791–98.
  24. 24. Nordmann P, Dortet L, Poirel L. Carbapenem resis tance in: here is the storm! Trends Mol Med. 2012; 18: 263.
  25. 25. Tzouvelekis LS et al. Carbapenemases inand other: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012; 25: 682.
DOI: https://doi.org/10.2478/prilozi-2014-0004 | Journal eISSN: 1857-8985 (formerly 0350-1914) | Journal ISSN: 1857-9345
Language: English
Page range: 31 - 38
Published on: Dec 1, 2014
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year

© 2014 Ana Kaftandzieva, Elena Trajkovska-Dokic, Vesna Kotevska, Zaklina Cekovska, Gordana Jankoska, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.